Neurogenic ED Treatment Ladder
Stepwise Management of Neurogenic ED: PDE5 by Lesion Level, Injection, Vacuum, and Implants
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Component therapies FDA-approved (PDE5 inhibitors, alprostadil, vacuum devices, penile prostheses)
Reference only. Not medical advice.
What can go wrong
Each rung carries its own risk: PDE5 inhibitors share the absolute nitrate contraindication; intracavernosal injection in denervated tissue carries a heightened risk of prolonged erection and priapism and requires careful low-dose titration; vacuum devices demand manual dexterity some disabled patients lack; and penile prosthesis is surgical with infection risk, though satisfaction is high. Any erection-inducing intervention can provoke autonomic dysreflexia in high spinal lesions.
This is something to take to a clinician. The Atlas can tell you what is known about neurogenic ed treatment ladder in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The treatment ladder for neurogenic ED follows the standard ED escalation but with a neurologic twist: response to each step depends on lesion level and the integrity of residual pathways. Oral PDE5 inhibitors are first-line and work best when an intact reflex arc or residual nitrergic innervation remains, for example, men with incomplete or upper-motor-neuron spinal lesions show markedly higher sildenafil response than those with complete lower-motor-neuron lesions, because PDE5 inhibitors require some preserved neural nitric-oxide signaling to amplify. Intracavernosal injection of alprostadil (and combinations) bypasses the nerves entirely and rescues most PDE5 failures. Vacuum erection devices are a non-pharmacologic option. Penile prostheses are highly effective and satisfying in neurogenic populations and are a strong, definitive choice rather than a mere fallback.
PDE5 response tracks lesion level; injection rescues most failures; and in this population the penile implant is not a last resort so much as a definitive, high-satisfaction option.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- PDE5 inhibitors
- First-line; best in incomplete/UMN lesions and preserved innervation
- Intracavernosal injection
- Bypasses nerves; rescues most PDE5 non-responders
- Vacuum erection device
- Non-pharmacologic; useful when drugs undesired or contraindicated
- Penile prosthesis
- Definitive, high-satisfaction option in neurogenic ED
How it works
PDE5 inhibitors block cGMP breakdown but require upstream neural nitric-oxide release; thus their efficacy mirrors residual neural integrity, high in incomplete and UMN lesions, low in complete LMN lesions and dense autonomic neuropathy. Intracavernosal alprostadil (prostaglandin E1) acts directly on cavernosal smooth muscle to raise cAMP and relax it, bypassing the nerves, which is why it works even when innervation is destroyed (with the caveat that denervated tissue can be more sensitive and prone to prolonged erection). Vacuum devices mechanically draw blood into the corpora and trap it with a constriction ring, requiring no innervation at all. A penile prosthesis replaces the erectile mechanism entirely, making it definitive regardless of nerve status.
PDE5 by lesion level, the predictive principle
The clinically decisive fact is that PDE5-inhibitor success is not random in neurogenic ED, it is predictable from the lesion. Trials in spinal cord injury showed sildenafil response rates far higher in men with incomplete or upper-motor-neuron lesions (who retain reflex arcs and some descending input) than in those with complete lower-motor-neuron lesions, who often respond poorly because there is little neural nitric oxide to amplify. The same logic explains poorer PDE5 response in dense diabetic autonomic neuropathy. Recognizing this prevents both false reassurance and premature abandonment: a poor PDE5 response in an LMN lesion is expected and signals a move to injection or implant, not therapeutic failure.
Safety in detail
- Denervated cavernosal tissue is more prone to prolonged erection/priapism with injection, start low, titrate carefully
- Vacuum devices require manual dexterity that some disabled patients lack, assess feasibility
- Penile prosthesis carries surgical/infection risk but high long-term satisfaction in neurogenic patients
- Watch for autonomic dysreflexia with any erection-inducing procedure in high spinal lesions
What people get wrong
Often saidA penile implant is only for when everything else fails
ActuallyIn neurogenic and diabetic ED, implants have among the highest satisfaction of any ED treatment and are a legitimate primary choice, not merely a last resort.
Often saidIf pills do not work, the man is out of options
ActuallyInjection, vacuum devices and prostheses all bypass the failed neural step and succeed across nearly all neurogenic causes.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Each rung trades autonomy for reliability: PDE5 pills are easiest but nerve-dependent; injections are reliable but invasive and carry priapism risk (heightened in neurogenic/denervated tissue); vacuum devices are drug-free but cumbersome; prostheses are definitive and durable but surgical and irreversible. In neurogenic populations the prosthesis earns an earlier and stronger place than in typical ED because the underlying lesion is fixed.
What we do not know
- Can neuromodulation or regenerative therapy restore PDE5 responsiveness in LMN lesions?
- What is the optimal earlier role for prostheses in fixed neurogenic lesions?
At a glance
- Step 1
- PDE5 inhibitors (response varies by lesion level)
- Step 2
- Intracavernosal injection (alprostadil / combinations)
- Alternative
- Vacuum erection device
- Definitive
- Penile prosthesis (high satisfaction)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Neurogenic ED Treatment Ladder. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Sildenafil RCTs in spinal cord injury1990s-2000s
Demonstrated efficacy overall but response stratified strongly by lesion level, higher in incomplete/UMN, lower in complete/LMN lesions
Penile prosthesis outcome series in neurogenic and diabetic populationsvarious
Report high satisfaction and reliability, supporting implants as a strong definitive option rather than a last resort
Intracavernosal alprostadil studies1990s onward
Established direct cavernosal action effective independent of neural integrity